Empagliflozin in Patients With Cirrhosis and Ascites

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
CirrhosisLiver Failure
Interventions
DRUG

Empagliflozin 10 MG

Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.

DRUG

Matching Placebo

Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.

Trial Locations (1)

06510

RECRUITING

Yale University, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Yale University

OTHER

NCT05726032 - Empagliflozin in Patients With Cirrhosis and Ascites | Biotech Hunter | Biotech Hunter